Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder.
Clinical
MOG antibody
NMOSD
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
01
11
2018
revised:
19
02
2019
accepted:
21
02
2019
pubmed:
3
3
2019
medline:
10
8
2019
entrez:
3
3
2019
Statut:
ppublish
Résumé
Serological antibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with a relapsing autoimmune demyelinating disease of the central nervous system. Initially identified in the context of acute disseminated encephalomyelitis, persistent seropositivity of MOG antibodies is now recognized as a variant of neuromyelitis optica spectrum disorder (NMOSD). The aim of the study is to describe the epidemiological and clinical features of MOG antibody positive cases and compare our findings with those previously published. This is a retrospective descriptive study of 23 patients with MOG antibody disease who were cared for at Johns Hopkins Hospital over the period from 2015 to 2018. MOG testing was done at Johns Hopkins using the cell based assay (CBA). We describe their epidemiological and clinical features. Twenty-three patients were included in the study with a female to male ratio of 2.3:1. The mean age of the cohort was 42.6 years, while the mean age at onset was 37 years. The most frequent initial presentation was optic neuritis, followed by ADEM-like encephalopathic clinical picture and transverse myelitis. Five patients showed a monophasic disease course while the rest experienced a relapsing phenotype. Nine patients (39%) experienced immediate relapses on withdrawal of steroids. Our cohort showed clinical characteristics comparable with previously published reports of MOG antibody disease worldwide. Unique features of MOG antibody disease are: high frequency of optic neuritis attacks, good long term neurological recovery and sensitivity to steroid use and withdrawal.
Sections du résumé
BACKGROUND
BACKGROUND
Serological antibodies against myelin oligodendrocyte glycoprotein (MOG) are associated with a relapsing autoimmune demyelinating disease of the central nervous system. Initially identified in the context of acute disseminated encephalomyelitis, persistent seropositivity of MOG antibodies is now recognized as a variant of neuromyelitis optica spectrum disorder (NMOSD).
OBJECTIVES
OBJECTIVE
The aim of the study is to describe the epidemiological and clinical features of MOG antibody positive cases and compare our findings with those previously published.
METHODS
METHODS
This is a retrospective descriptive study of 23 patients with MOG antibody disease who were cared for at Johns Hopkins Hospital over the period from 2015 to 2018. MOG testing was done at Johns Hopkins using the cell based assay (CBA). We describe their epidemiological and clinical features.
RESULTS
RESULTS
Twenty-three patients were included in the study with a female to male ratio of 2.3:1. The mean age of the cohort was 42.6 years, while the mean age at onset was 37 years. The most frequent initial presentation was optic neuritis, followed by ADEM-like encephalopathic clinical picture and transverse myelitis. Five patients showed a monophasic disease course while the rest experienced a relapsing phenotype. Nine patients (39%) experienced immediate relapses on withdrawal of steroids.
CONCLUSIONS
CONCLUSIONS
Our cohort showed clinical characteristics comparable with previously published reports of MOG antibody disease worldwide. Unique features of MOG antibody disease are: high frequency of optic neuritis attacks, good long term neurological recovery and sensitivity to steroid use and withdrawal.
Identifiants
pubmed: 30825703
pii: S2211-0348(19)30100-2
doi: 10.1016/j.msard.2019.02.023
pmc: PMC6467709
mid: NIHMS1522912
pii:
doi:
Substances chimiques
Antibodies
0
Aquaporin 4
0
Myelin-Oligodendrocyte Glycoprotein
0
Types de publication
Journal Article
Langues
eng
Pagination
231-235Subventions
Organisme : NINDS NIH HHS
ID : K08 NS078555
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI130548
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163
pubmed: 26516628
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):132-136
pubmed: 27951522
Brain. 2017 Dec 1;140(12):3128-3138
pubmed: 29136091
J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):242
pubmed: 25136054
JAMA Neurol. 2014 Jul 1;71(7):924
pubmed: 25023554
JAMA Neurol. 2013 Nov;70(11):1375-81
pubmed: 23999580
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89
pubmed: 25821844
Mult Scler. 2015 Jun;21(7):866-874
pubmed: 25344373
Mult Scler. 2015 Oct;21(12):1513-20
pubmed: 25662345
J Neuroinflammation. 2016 Nov 1;13(1):282
pubmed: 27802824
Mult Scler. 2017 Sep;23(10):1377-1384
pubmed: 27885065
J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):811-817
pubmed: 28684532
JAMA Neurol. 2018 Jan 1;75(1):65-71
pubmed: 29131884
Neurology. 2017 Jul 18;89(3):269-278
pubmed: 28615429
Pediatrics. 2016 May;137(5):
pubmed: 27244783
Curr Opin Neurol. 2017 Jun;30(3):295-301
pubmed: 28248700
Mult Scler Relat Disord. 2018 Oct;25:66-72
pubmed: 30048919
Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
pubmed: 27458601
Neurol Neuroimmunol Neuroinflamm. 2017 Jan 16;4(2):e322
pubmed: 28105459
Neurology. 2018 May 22;90(21):e1858-e1869
pubmed: 29695592
Arch Neurol. 2011 Nov;68(11):1412-20
pubmed: 21747007
Eur J Neurol. 2016 Mar;23(3):580-7
pubmed: 26593750
Mult Scler. 2016 Feb;22(2):174-84
pubmed: 26041801
Mult Scler Relat Disord. 2018 Oct;25:87-94
pubmed: 30056361
Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40
pubmed: 25364774
Neurology. 2014 Feb 11;82(6):474-81
pubmed: 24415568
Brain. 2017 Mar 1;140(3):617-627
pubmed: 28364548
J Neuroinflammation. 2016 Sep 27;13(1):280
pubmed: 27793206
Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225
pubmed: 27144216
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137
pubmed: 29142145